Skadden Advises CureVac on Acquisition by BioNTech

Skadden is advising CureVac N.V. on its definitive purchase agreement with BioNTech SE, pursuant to which BioNTech intends to acquire all of the shares of CureVac. Under the terms of the purchase agreement, each CureVac share will be exchanged for approximately $5.46 in BioNTech American depositary shares, resulting in an implied aggregate equity value for CureVac of approximately $1.25 billion, subject to certain adjustments. The transatlantic Skadden team is led by M&A partner Holger Hofmeister and capital markets partner Stephan Hutter and counsel Caspar Schmelzer. M&A partners Howard Elin and June Dipchand also advised.